RegulationOrphan Drug (United States), Breakthrough Therapy (China), Conditional marketing approval (China), Special Review Project (China), Priority Review (China)

Structure/Sequence

Molecular FormulaC22H19FN4O2

InChIKeySZMJVTADHFNAIS-BJMVGYQFSA-N

CAS Registry1616493-44-7

269

Clinical Trials associated with Chidamide

NCT07081607

/ Not yet recruitingPhase 2IIT

An Open-label, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib Combined With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

In decades, the outcome of patients with peripherial T-cell lymphomas is dismal, especially in relapsed or refractory population. After failure to the frontline treatment, patients have limited treatment options and elderly population usually have no chance to undergo transplantation due to age or comorbidity, etc. Golidocitinib and chidamide were approved in treating r/r PTCL in China, while azacytidine has been demonstrated its anti-tumor activity in PTCL as well.
This study aims to explore the efficacy and safety of golidocitinib combined with azacytidine and chidamide in the patients with peripheral T-cell lymphoma who are eligible for intensive chemotherapy or transplantation.

Start Date15 Jul 2025

Sponsor / Collaborator-

NCT06947967

/ Not yet recruitingPhase 3

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter Study of Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype (SWIFT 02)

A Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype

Start Date01 Jun 2025

Sponsor / Collaborator

Shenzhen Chipscreen Biosciences Co., Ltd.

NCT06570447

/ RecruitingPhase 2IIT

An Open-label, Single-arm, Single-center, Phase II Clinical Trial of Glofitamab Combination With Chidamide in Patients With Recurrent and Refractory Diffuse Large B-Cell Lymphoma

An open-label, single-arm, single-center, phase II clinical trial to evaluate the feasibility, efficacy and safety of Glofitamab Combination with chidamide in patients with recurrent/refractory diffuse large B-cell lymphoma.

Start Date15 May 2025

Sponsor / Collaborator

Tianjin Medical University Cancer Institute and Hospital

100 Clinical Results associated with Chidamide

100 Translational Medicine associated with Chidamide

100 Patents (Medical) associated with Chidamide

2,535

Literatures (Medical) associated with Chidamide

01 Dec 2025·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Recent progress in synthetic strategies to develop potent, HDAC8-selective, small-molecule inhibitors

Review

Author: Fletcher, Steven ; Lowe, Brandon D

Key players in epigenetic control, the 11 zinc-dependent histone deacetylase (HDAC) enzymes have been affirmed as therapeutic targets, particularly in the discovery of new chemotherapy drugs: currently there are 3 FDA-approved pan-HDAC inhibitors (HDACi's), although these are not without their side effects. It has been rationalized that achieving HDAC isoform-selective inhibitors may yield safer drugs. HDAC8 has recently been validated as a novel target for the treatment of (pediatric) neuroblastoma, and its overexpression has been implicated in a range of other diseases. Herein, we discuss the topology of the HDAC8 active site in the context of inhibitor design, and we present recent progress in the discovery of potent, HDAC8-selective small-molecule inhibitors, with a discussion on the particular structural criteria required. HDACi's largely conform to a canonical pharmacophore model of a capping group connected via a linker to a zinc binding group (ZBG), which is typically a (potentially mutagenic) hydroxamic acid. In particular, for HDAC8-selectivity, the small-molecule should adopt a geometric "L"-shape, which may be accomplished by the linker itself, or the linker and capping group. More recently, HDAC isoform selectivity has been realized with hydroxamic acid surrogates, such as ortho-aminoanilides that yield potent and HDAC1-3-selective (but HDAC8-inactive) inhibitors. Hydrazides have long been utilized as bioisosteres of hydroxamic acids in HDAC inhibitor design, but a recent re-visiting explored the attachment of alkyl groups, and an n-hexyl substituent on the distal, non-acylated nitrogen affords potent and selective HDAC8 inhibitors probably through targeting the foot pocket of the active site; this discovery was observed across three different HDACi scaffolds, and thus appears quite general. α-Aminoketo ZBGs have also demonstrated HDAC8-selectivity, with associated benzylic moieties likewise engaging the foot pocket. We speculate that a re-imagining of the ortho-aminoanilide ZBG through a careful and methodical survey of related moieties, may lead to the discovery of additional HDAC8-selective ZBGs towards the realization of safe, pre-clinical inhibitors. 2025 Elsevier Ltd. All rights reserved.

01 Oct 2025·BIOCHEMICAL PHARMACOLOGY

Therapeutic potential of HDAC inhibitors in a xenograft model of cancers: A special focus on breast cancer

Review

Author: Sinha, Suman ; Vora, Lalitkumar K ; Babu, Raja ; Pancholi, Bhaskaranand ; Khatri, Dharmendra Kumar ; Garabadu, Debapriya ; Manhar, Nirmal

Histone deacetylase inhibitors (HDACi) have emerged as promising agents in cancer therapy, particularly in breast cancer treatment. In this context, it is postulated that HDACi exhibits strong antiproliferative effects on breast cancer cells, regulating the cell cycle, modulating the immune response, triggering apoptosis, suppressing tumour growth, and reducing angiogenesis. Their ability to modify the acetylation status of histone proteins and other nonhistone targets has shown significant anticancer activity. However, there is less information on their application in clinical breast cancer treatment. Moreover, the ability of patient-derived xenograft (PDX) models of breast cancer to replicate the genetic and histological heterogeneity of human tumours has made them practical tools in preclinical research. This review focuses on the fate of the anticancer activity of HDACi in a PDX model of breast cancer, which serves as an essential experimental tool to evaluate the efficacy and safety of these molecules in vivo. The results highlight the promise of HDACi in treating breast cancer in PDX models, providing information on their mechanisms of action and encouraging further investigations in clinical studies. The present study also highlights the importance of personalized treatment strategies for controlling the progression of breast cancer.

01 Oct 2025·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Epigenetic targeting of DNA damage response (DDR)-related mechanisms to overcome acquired cisplatin resistance of tumor cells

Article

Author: Abbey, Lena ; Sekeres, Marlena ; Fischer, Fabian ; Lengle, Daniel ; Kassack, Matthias Ulrich ; Kurz, Thomas ; Fritz, Gerhard

Mechanisms of the DNA damage response (DDR) are considered as useful targets to overcome tumor cell resistance. We investigated the impact of various classes of histone deacetylase inhibitors (HDACi) (i.e. broad-spectrum HDACi (vorinostat), class I HDACi (entinostat), preferential class IIb HDAC6i (ricolinostat) and dual HDAC class I/IIb inhibitors (HDAC1/6i)) on mechanisms of the DDR using parental (J82^WT) and cisplatin (CisPt)-resistant bladder carcinoma cells (J82^CisR). Mono-treatment with entinostat revealed relatively low genotoxic and DDR-activating potency, while showing similar antiproliferative, cytotoxic and pro-apoptotic activities as the other HDACi. Despite its low DNA double-strand break (DSB) forming potency with mono-treatment, entinostat conferred the highest synergistic cytotoxicity (CI ≤ 0.8) in J82^CisR following co-treatment with cisplatin. Notably, this effect is independent of Pt-(GpG)-DNA-intrastrand-crosslink formation. Entinostat increased the level of CisPt-induced DNA strand-breaks, promotes replication and transcription blockage, pRPA32 foci formation, PARP- and caspase-7 cleavage, influenced the activation of DDR-related factors (e.g. γH2AX, pp53, pRPA32, pKap1), reverted CisPt-induced p53 acetylation and blocked drug-stimulated mRNA expression of multiple DSB (HR, NHEJ)- and BER repair-related factors. Summarizing, the class I-selective HDACi entinostat reveals the lowest DDR-activating potency in mono-treatment and the highest anticancer efficacy in combination with CisPt, likely involving inhibition of HDAC3. This is due to amplification of replicative and transcriptional stress caused by CisPt treatment as well as interference with mechanisms of DDR and DNA repair, eventually promoting apoptosis. Thus, epigenetic targeting of DDR-related death pathways by class I HDACi is useful to overcome acquired CisPt resistance of tumor cells.

News (Medical) associated with Chidamide

01 Jul 2025

·cerenoscientific.com

Cereno Scientific is included in Nasdaq’s First North 25™ Index

01 Jul 2025 06:00 Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company is added to the First North 25™ Index (FN25 Index). The Index gathers a selection of the largest and most traded securities on the Nasdaq Nordic First North Growth Markets. The inclusion is effective at market open on Tuesday, July 1, 2025. "Being included in the First North 25 Index is a proud milestone for Cereno Scientific and a reflection of the progress we have made in building a strong and credible biotech company. It also represents the trust and long-term belief placed in us by our shareholders, who continue to support our mission to develop pioneering treatments for patients with rare cardiovascular and pulmonary diseases. We remain focused on delivering scientific, clinical, and strategic value for patients and shareholders as we move forward,” said Sten R. Sörensen, CEO at Cereno Scientific. The First North 25 Index measures the performance of a selection of the largest and most traded securities listed on the Nasdaq Nordic First North Growth Markets (First North Denmark, First North Finland, First North Iceland and First North Sweden). Further information is available on https://indexes.nasdaqomx.com/Index/Overview/FN25 For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 1Phase 2

30 Jun 2025

·cerenoscientific.com

Cereno Scientific shares that the top-line results of the CS014 Phase I trial will be communicated in mid-July

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the top-line results of CS014’s Phase I trial will be announced mid-July 2025. The previously communicated timeline was June 2025. The Phase I trial is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers. "The first-in-human Phase I trial of CS014 was successfully conducted and concluded in April. Since then, the contract research organization (CRO) has followed standard procedures in collating, verifying and analyzing data to prepare the study report. We look very much forward to the top-line results in mid-July and the next stage of the development program for CS014 to start this fall,” said Sten R. Sörensen, CEO at Cereno Scientific. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action. Being an epigenetic modulator, CS014 has the potential to target the underlying pathophysiology of several rare cardiovascular and pulmonary diseases with high unmet medical needs. The initial target indication is idiopathic pulmonary fibrosis (IPF). The Phase I trial evaluated safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers. The trial was conducted in two parts: part one explored safety, tolerability and PK of single ascending oral doses (SAD) of CS014; part two explored safety, tolerability, PK, and PD following multiple ascending doses (MAD) of CS014, dosed for seven days. In total, 48 subjects were included in the trial, 30 in the SAD and 18 in the MAD part. The trial was conducted in Sweden. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 1Phase 2Clinical Result

20 Jun 2025

·cerenoscientific.com

Cereno Scientific secures 100 MSEK through additional loan financing and conversion to advance HDAC inhibitors CS1 and CS014 in Phase II

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced entering loan financing agreements securing a total of 100 MSEK. The financing is achieved through an addendum (the “Addendum”) to the loan financing agreement (the “Original Financing Agreement”) entered in November 2024 with Fenja Capital II A/S and the US-based investor Arena Investors, LP (the “Original Financiers”) and additionally entering into a new loan agreement (the “New Financing Agreement”) with Danish investors Venusat ApS and SAJ Finans ApS (the “New Financiers”). The New Financing Agreement secures a new cash loan of 25 MSEK (the “New Loan”) whereas the Addendum secures an advanced payment of the second tranche of 50 MSEK according to the Original Financing Agreement and the Original Financiers requesting conversion of 25 MSEK of their outstanding convertibles. “This is an important continuation of the strategic financing that we completed in November 2024, allowing us to maintain flexibility while providing runway to reach key clinical and regulatory milestones for CS1 and CS014. We currently have two HDAC inhibitor programs in clinical development, a preclinical candidate advancing in its program, a growing IP portfolio, and strong scientific and regulatory momentum. With this financing, we are advancing two Phase II programs with promising drug candidates with potential to enhance and improve lives of patients with rare cardiovascular and pulmonary disease. Cereno Scientific is well-positioned for further growth and set-up for future clinical success,” said Sten R. Sörensen, CEO of Cereno Scientific. Background and rationale for the Addendum and the New Financing Agreement Cereno Scientific is pioneering treatments to enhance and extend life. The company is advancing a pipeline that includes an HDAC inhibitor portfolio with two drug candidates in clinical phase: CS1 having completed a Phase IIa trial and CS014 that have recently completed a Phase I trial. The HDAC inhibitor portfolio has an innovative disease-modifying approach to addressing the root mechanism of rare and fatal diseases, untapping the potential of epigenetic modulation in rare cardiovascular and pulmonary diseases. In preclinical stage, drug candidate CS585, a novel prostacyclin (IP) receptor agonist, has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. Cereno Scientific has the potential to deliver high treatment value to people that are suffering from rare cardiovascular and pulmonary diseases who today have unmet medical needs. Cereno Scientific is well-positioned to continue its trajectory toward becoming a leader in epigenetically modulating therapies for rare cardiovascular and pulmonary diseases. To maintain the momentum following several successful achievements across the company’s pipeline and business, Cereno Scientific’s Board of Directors has decided to enter into the Addendum and the New Financing Agreement with the Financiers and the New Financiers respectively. The injected capital and lowered debt burden ensures the company's ability to pursue the development of the HDAC inhibitor portfolio with CS1 and CS014 to reach key regulatory and clinical milestones. Additionally, it establishes favorable conditions for conducting business development activities, including discussions concerning partnerships for the company's development programs. The proceeds from the Addendum and the New Financing Agreement are primarily intended for: Advancing CS1 Phase IIb trial to initiation through preparation of regulatory documentation, obtaining approvals and conducting start-up activities Initiating a Phase II program for CS014 Progressing the Expanded Access Program (EAP), including the Fluidda sub-study, to gain insights into the long-term use of CS1 in patients with pulmonary arterial hypertension (PAH) Continuing and expanding the company’s global partnering activities Continuing to strengthen footprint in the scientific community through publications and presentations “Cereno Scientific has great momentum with an impressive list of milestones achieved during the past year, setting us up for future success. We are pleased to have secured this strategic financing together with our partners Fenja, Arena and the new partners Venusat and SAJ Finans, enabling the continued pursuit of the development program. We will remain focused on long-term value creation and responsible capital allocation to support continued growth and clinical development in our focus indications where high unmet medical needs persist,” said Jeppe Øvlesen, Chair of the Board at Cereno Scientific. Main terms of the Addendum and the New Finance Agreement The secured financing is divided into three components: (i) the New Loan of 25 MSEK from the New Financiers, (ii) the advance payout from the Original Financiers of 50 MSEK (Tranche 2) under the Original Financing Agreement and (iii) the Original Financiers converting outstanding convertibles (the “Convertibles”) to a total amount of 25 MSEK (the “Conversion”) into new B-shares in the company at the pre-determined subscription price of 6.09 SEK per B-share. The New Loan is subject to a customary setup fee amounting to approximately 3.1 MSEK, which considers the total amount of 100 MSEK secured under the financing structure now presented. Repayment of the New Loan, together with the loans issued under the Original Financing Agreement (including both tranches) shall be made on 30 April 2026. The interest rate of all outstanding loans to the New Financiers and the Original Financiers is fixed annually starting at the time of payment and bears an annual interest rate set at the percentage rate per annum which is the sum of STIBOR plus 11 percentage points. Conversion of the Convertibles Through the Conversion of the Convertibles, the number of shares in Cereno Scientific will increase by 4,105,090 B-shares and the share capital will increase by SEK 410,509 corresponding to a dilution effect of approximately 1.43 per cent of the currently outstanding shares in the company and approximately 1.40 per cent of the currently outstanding votes in the company. Following Conversion, the Original Financiers hold outstanding convertibles to a nominal amount of 50 MSEK. About Fenja Capital Fenja Capital is an independent specialized asset manager and the leading capital partner for small and midsized listed companies in the Nordics. Fenja Capital manages two investment funds with a focus on innovative companies; mainly within technology, biotech and healthcare, and have invested 10bn SEK in these segments since inception in 2015. About Arena Investors Arena Investors, LP is an institutional asset manager founded in partnership with The Westaim Corporation (TSXV: WED). With approximately 4bn USD of invested and committed assets under management as of October 1st, 2024, and a team of over 180 employees in offices globally, Arena provides creative solutions for those seeking capital in special situations, alongside operational capabilities to manage and improve businesses. The firm brings individuals with decades of experience, a track record of comfort with complexity, the ability to deliver within time constraints, and the flexibility to engage in transactions and business operations that cannot be addressed by banks and other conventional financial institutions. See www.arenaco.com for more information. About Venusat and SAJ Finans Venusat and SAJ Finans are the two entrepreneurs behind Yggdrasil Commodities, a Danish power trading company founded in 2018 and deeply rooted in an entrepreneurial mindset. Building on this track record, Venusat and SAJ Finans aim to broaden their investment reach, support high potential ventures, and foster sustainable value creation across diverse markets. Advisers MAQS Advokatbyrå has been the legal adviser to the company and Baker & McKenzie Advokatbyrå has been the legal adviser to the New Financiers and the Original Financiers in connection with the company’s financing under this press release. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 This information is information that Cereno Scientific AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:55 CET on June 20, 2025. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 2Phase 1Clinical Result

100 Deals associated with Chidamide

External Link

KEGG	Wiki	ATC	Drug Bank
-	Chidamide	L01XX	DB06334

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diffuse Large B-Cell Lymphoma	China	Shenzhen Chipscreen Biosciences Co., Ltd.	24 Apr 2024
Adult T-Cell Leukemia-Lymphoma	Japan	Meiji Seika Pharma Co., Ltd.	23 Jun 2021
Breast Cancer	China	Shenzhen Chipscreen Biosciences Co., Ltd.	20 Nov 2019
Peripheral T-Cell Lymphoma	China	Shenzhen Chipscreen Biosciences Co., Ltd.	23 Dec 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Unresectable Colorectal Carcinoma	Phase 3	China	Shenzhen Chipscreen Biosciences Co., Ltd.	27 Nov 2024
Metastatic Microsatellite Stable Colorectal Carcinoma	Phase 3	China	Sun Yat-Sen University	01 Mar 2023
Microsatellite Stable Colorectal Carcinoma	Phase 3	China	Sun Yat-Sen University	01 Mar 2023
Brain metastases	Phase 3	United States	Huyabio International LLC	12 Aug 2021
Brain metastases	Phase 3	United States	Bristol Myers Squibb Co.	12 Aug 2021
Brain metastases	Phase 3	Japan	Huyabio International LLC	12 Aug 2021
Brain metastases	Phase 3	Japan	Bristol Myers Squibb Co.	12 Aug 2021
Brain metastases	Phase 3	Australia	Huyabio International LLC	12 Aug 2021
Brain metastases	Phase 3	Australia	Bristol Myers Squibb Co.	12 Aug 2021
Brain metastases	Phase 3	Austria	Bristol Myers Squibb Co.	12 Aug 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04562311 (ASCO2025) Manual	Phase 2	Advanced Urothelial Carcinoma	45	Chidamide + tislelizumab	pochcxobha(hulqxnlwhl) = bagizqzwir muvywipmip (zygrmbsudj, 29.6 - 60.0) View more	Positive	30 May 2025
ChiCTR2400080783 (B-Enefits/SCOG-B001, ASCO2025) Manual	Phase 2	Biliary Tract Neoplasms First line	35	Envafolimab + Chidamide + GEMOX	nzdvemwuua(fhwlmcwpjd) = qygxxsmqtq tpscsyjvma (fgnusfedbn ) View more	Positive	30 May 2025
NCT05586841 (ASCO2025) Manual	Phase 1	Hormone receptor positive HER2 negative breast cancer HER2 Negative \| Hormone Receptor Positive	22	dalpiciclib + chidamide	slnzzcjzth(ajysnkpuni) = the MTD was established as Group C (dalpiciclib 100 mg/d, chidamide 25 mg BIW). bqfrwanpuy (voffhpcsvx )	Positive	30 May 2025
NCT05586841 (ASCO2025) Manual	Phase 1		22	dalpicicldalpiciclibchidamide (Group C: dalpiciclib 100 mg/d, chidamide 25 mg BIW)		Positive	30 May 2025
NCT06584227 (ADEPT, ASCO2025) Manual	Phase 2	Pancreatic Cancer First line	13	Adebrelimab + Chidamide + Gemcitabine + S-1	rlkceerqbo(cfguieujuq) = gjfqwkavpk psukjpasmd (lcayvmctvz, 7.0–13.3) View more	Positive	30 May 2025
NCT04025931 (ASCO2025) Manual	Phase 2	Soft Tissue Sarcoma	69	Chidamide + toripalimab	uicfrzoaji(nbojvyzxsb) = vtvfrhojah mvqziqaxue (esfxwvulus ) View more	Positive	30 May 2025
NCT04994210 (SCENT-2, ASCO2025) Manual	Phase 2	Extranodal NK-T-Cell Lymphoma \| T-Cell Lymphoma First line	47	Sintilimab + Chidamide (part A)	tfrcyaqovt(pisbtmebun) = rvjfubupca vvzqgubfuf (lktpizwypo ) View more	Positive	30 May 2025
NCT04994210 (SCENT-2, ASCO2025) Manual	Phase 2	Extranodal NK-T-Cell Lymphoma \| T-Cell Lymphoma First line	47	Sintilimab + Chidamide + P-GemOx (part A+part B)	tfrcyaqovt(pisbtmebun) = wtrijoviux vvzqgubfuf (lktpizwypo ) View more	Positive	30 May 2025
NCT05958719 (IIT2023003, EHA2025) Manual	Phase 2	Peripheral T-Cell Lymphoma First line	13	chidamidechidamide in combination with azacitidine, mitoxantrone liposomesazacitidine, mitoxantrone liposomes and prednisone	qyhjhgetpo(sqmxpesdre) = kxnqhsaqbx exflocnaxf (trpruidojk ) View more	Positive	14 May 2025
PF1008 (EHA2025)	Not Applicable	T-Cell Lymphoma CD7+	-	Chidamide	nwoplnuyuu(qdldqdscab) = ohirtqhfrj qiqgditiyi (ykxbutmqkj ) View more	-	14 May 2025
PB2330 (EHA2025)	Not Applicable	Pre B-cell acute lymphoblastic leukemia IKAROS \| TCL1A	-	CX-4945 + CHI	jiofexhdri(gzbpfldxfw) = xlruwqjwdi qyndkjgwvz (bognpswzdn ) View more	-	14 May 2025
PS1386 (EHA2025)	Not Applicable	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma BCL-2	13	Venetoclax	traudnqhjo(zkkwamesny) = 84% mjubgqdvru (xsgpndfifj ) View more	-	14 May 2025
PS1386 (EHA2025)	Not Applicable	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma BCL-2	13	Tucidinostat		-	14 May 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Chidamide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation